MedTrace Logo

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

NCT04916093 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-07

No results posted yet for this study

Summary

The current study aims to investigate Sitagliptin and vildagliptin efficacy and safety compared to metformin as 1st line options for T2D patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin 50 MG

Galvus 50 mg oral tablets

DRUG

Sitagliptin 100mg

Januvia 100mg oral tablets

DRUG

MetFORMIN 1000 Mg Oral Tablet

Glucophage 1000 mg oral tablets

Sponsors & Collaborators

  • Minia University

    collaborator OTHER

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Asmaa A Elsayed, Master · BUC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-06-10
Completion
2020-12-15
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916093 on ClinicalTrials.gov